A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2015
At a glance
- Drugs Kanglaite (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Zhejiang Kanglaite Pharmaceutical
- 16 Jun 2015 Status changed from discontinued to completed as per ClinicalTrials.gov record.
- 24 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 10 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History